Neratinib and metformin: A novel therapeutic approach against HER2-Positive Breast Cancer

Neratinib and metformin: A novel therapeutic approach against HER2-Positive Breast Cancer

BackgroundHER2-positive breast cancer (BC) is highly aggressive with a poor prognosis. It is driven by HER2 oncoprotein activation/crosstalk with other receptors like EGFR/(HER1), HER3, and HER4, in addition to IGF-1R, making these receptors ideal therapeutic targets as they are expressed/overexpres...

Full description

Saved in:
Bibliographic Details
Main Author: Kheraldine, Hadeel (author)
Other Authors: Hassan, Arij Fouzat (author), Saeed, Sumayyah (author), Merhi, Maysaloun (author), Mateo, Jericha Miles (author), Ulamec, Monika (author), Peric-Balja, Melita (author), Vranic, Semir (author), Al-Thawadi, Hamda (author), Moustafa, Ala-Eddin Al (author)
Format: article
Published: 2025
Subjects:
HER2-positive breast cancer
Neratinib
Metformin
EGFR
HER3
IGF-1R
Angiogenesis
Online Access:http://dx.doi.org/10.1016/j.biopha.2025.118034
https://www.sciencedirect.com/science/article/pii/S0753332225002288
http://hdl.handle.net/10576/65155
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://dx.doi.org/10.1016/j.biopha.2025.118034
https://www.sciencedirect.com/science/article/pii/S0753332225002288
http://hdl.handle.net/10576/65155

Similar Items